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Abstract 16 
Background 17 
Trade agreements in the 21st century have evolved to include provisions that affect domestic public 18 
policy and public health in signatory countries. There are growing calls for health professionals and 19 
public health advocates to pursue an active advisory role in trade negotiations in order to anticipate 20 
and prevent negative outcomes for health services and public health.  21 
Aim 22 
This scoping review explored current literature to identify existing knowledge of the implications of 23 
trade agreements for the nursing workforce, nursing practice and public health using as an example 24 
the 2018 ‘Comprehensive and Progressive Agreement for Trans-Pacific Partnership’. 25 
Design 26 
Scoping review 27 
Data Sources 28 
Emerald Insight, Informit, Ovid MEDLINE, PubMed, ProQuest, Scopus, and a number of specialist 29 
Economics, International Trade and Business, and International Relations databases. Grey literature 30 
included national and international policy documents.   31 




Review Method 32 
Literature was selected according to extraction field criteria, supplemented by hand searching of 33 
relevant grey literature and snowballing references from the selected literature reference lists. 34 
Analysis was undertaken to identify key themes emerging from the literature.  35 
Review results 36 
Six key themes relevant to nursing workforce, nursing practice or public health were 1. Lack of 37 
consultation with public health and health professionals in trade negotiations; 2. Implications of 38 
strengthened intellectual property provisions for equitable access to medicines (including biologics) 39 
and medical devices; 3. Threats to government capacity to regulate domestic policy for public health 40 
and health services through ‘Investor State Dispute Settlement’ provisions 4. Threats to government 41 
capacity to regulate domestic policy for public health and health services through ‘Regulatory 42 
Coherence’ 5. Potential limited benefits to communities and increased health inequities 6. Potential 43 
implications of increased temporary migration. Gaps were identified in the literature for implications 44 
for nursing practice and the nursing workforce from regulatory and labour provisions of trade 45 
agreements.  46 
Conclusions 47 
The analysis of the literature reviewed is of international importance for the nursing workforce, 48 
nursing practice and public health.  Policymakers must anticipate and respond to how the inclusion 49 
of labour or regulatory provisions in trade agreements will affect nursing practice and the nursing 50 
workforce, and how this may subsequently impact on the health of communities globally. 51 
Keywords 52 
Nursing, Nursing workforce, Public Health, Scoping review, Trade in services, Trade agreement, 53 
Health services. 54 
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What is already known about this topic? 56 
 There is limited evidence in the international literature on the impact of trade in goods and 57 
services agreements on the nursing workforce, nursing practice and public health. 58 
 Some prospective analyses and commentaries have, nonetheless, considered and described 59 
potential implications of trade in goods and services agreements for public health.  60 
 There is evidence that concerns raised by health advocates have resulted in the suspension 61 
of some controversial provisions of the Comprehensive and Progressive Agreement for 62 
Trans-Pacific Partnership, although they have not been cancelled and may be reintroduced. 63 
Many of the suspended provision have now been introduced into the recent United States, 64 
Mexico, Canada Agreement (2018) while others such as ‘Regulatory Coherence’ have been 65 
expanded and strengthened. 66 
 67 
What this paper adds? 68 
• Provisions of trade in goods and services agreements have the capacity to adversely impact 69 
on the nursing workforce, nursing practice and public health. 70 
• Gaps in the peer reviewed literature were identified for risks to the nursing workforce, 71 
nursing practice and public health from regulatory and labour provisions in the agreements.    72 
• Further research into the potential benefits and challenges of each of these provisions in 73 
trade in goods and services agreements to the nursing workforce, nursing practice and 74 
public health is urgently required. 75 
• Increased intrusions of trade agreement provisions into domestic public policy have risks for 76 
health services and public health. Health professionals, including nurses, and public health 77 
advocates must be afforded the same access to trade negotiators as traditional advisors in 78 
trade, finance and business law and that their subsequent advice is factored into trade 79 
agreements. 80 
 81 




Trade agreements and the risks for the nursing workforce, nursing practice and public health: A 82 
scoping review  83 
 84 
1. Introduction 85 
The past two decades have seen a rapid increase in the number of trade agreements negotiated 86 
outside the World Trade Organization (WTO). Trade agreements in the 21st century have evolved to 87 
include provisions that affect domestic public policy and public health in signatory countries. 88 
Protections for health, which were established through the WTO, are being marginalised and new 89 
provisions place far greater constraint on domestic policy making (Gleeson & Labonté, 2020; 90 
Gleeson, Lexchin, Labonté, Townsend, Gagnon, Kohler, Forman & Shadlen, 2019). Issues such as 91 
intellectual property (patent) protections also continue to present a challenge to equitable global 92 
access to medicines (including biologics) and medical devices as pharmaceutical companies pursue 93 
new ways to extend product protection. Over the same period, there has been a growth in the 94 
power of markets to influence negotiation of these agreements. Trade agreements represent a point 95 
of potential conflict between public policy goals, the provisions of essential services and the profit 96 
motive of markets and trade.  97 
 98 
These changes in trade agreements are occurring in the global context of increased demand for 99 
health services and the health workforce. At the same time, there is increased focus on the 100 
importance of the nursing workforce in the delivery of those services and in the achievement of the 101 
United Nations Sustainability Development Goals by 2030. For the nursing profession, these 102 
agreements have potential implications for nursing practice, the nursing workforce and workforce 103 
planning for sustainable and equitable health service delivery. 104 
 105 
1.1 Brief History  106 




The General Agreement on Tariffs and Trade, established in 1947, had both an economic and 107 
political purpose. Following the devastation of two world wars and the great depression in the early 108 
twentieth century, it was believed that increasing the wealth of countries and linking them through 109 
trade would promote peace and prosperity. The agreement led to a massive expansion of world 110 
trade which raised millions of people out of poverty (Johnston, 2019; Labonté, 2019; Schram, 111 
Townsend, Youde, & Friel, 2019). In 1995, the General Agreement on Tariffs and Trade became the 112 
WTO which now includes 164 member countries. The WTO oversees a number of international trade 113 
agreements, including the General Agreement on Trade in Services, the Agreement on Trade Related 114 
Intellectual Property Rights, and the Agreement on Trade Related Investment Measures.  115 
The negotiations of agreements through the WTO were painfully slow and complex, requiring 116 
consensus across a large number of countries and economies at different stages of development. 117 
Countries struggled to agree on trade rules for such things as patent and data exclusivity protections 118 
for medicines and medical devices.  Many countries have now turned away from the multilateral 119 
process toward bilateral or regional trade agreements and there has been a rapid increase in the 120 
number of these agreements in the past two decades (Johnston, 2019; McNeill, Birkbeck, Fukuda-121 
Parr, Grover, Schrecker & Stuckler, 2017; Labonté et al. 2019, Bureau et al. 2019).   122 
Trade agreements form a type of economic legal framework of rules and principles governing global 123 
trade. Some commentators believe that the forces influencing the development of those rules 124 
globally are increasingly dominated by private economic powers and very powerful countries 125 
(Schram et al. 2019). At the same time, there has been a strong growth in neoliberalism, which 126 
favours deregulation, reducing government spending, cutting taxes, competition and free markets. 127 
The International Monetary Fund has noted that this strong global trend to neoliberalism has led to 128 
increasing inequality rather than growth (Ostry, Loungani, & Furceri, 2016).  129 
Traditionally, the policy areas of trade and health have operated separately (Gleeson & Labonté, 130 
2020). However, these changes to trade agreements, coupled with increased cross-border flows in 131 




goods, services, people and capital, affect public health and health services through a number of 132 
mechanisms (Smith, Blouin, &Drager, 2015). These mechanisms include the increased advertising 133 
and sale of unhealthy products, such as high sugar content foods and beverages, increased costs of 134 
medicines to health systems and consumers, ownership and capital investment by large 135 
international organizations in health infrastructure, and through impacts on key determinants of 136 
health such as employment, pollution and the environment (Smith, Blouin, & Drager, 2015; Gleeson 137 
& Labonté, 2020; Labonté et al. 2019; Schram et al. 2019). 138 
The Comprehensive and Progressive Agreement for Trans-Pacific Partnership is one of the regional 139 
trade agreements negotiated outside of the WTO. The signatory countries are Australia, Brunei 140 
Darussalam, Canada, Chile, Japan, Malaysia, Mexico, Peru, New Zealand, Singapore and Vietnam. 141 
There is a broad range of economic development across these countries from advanced, high-142 
income economies such as Japan, to developing, lower middle-income economies such as Vietnam. 143 
 144 
Based on the Trans-Pacific Partnership (2016), which faltered after the withdrawal of the United 145 
States in 2017, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership is 146 
fundamentally the same agreement with suspension of some of the more contentious provisions.   147 
These suspensions remain in place unless the signatory countries unanimously agree that they are 148 
reintroduced. The suspended provisions of relevance to this discussion relate primarily to provisions 149 
that would have strengthened patent and data exclusivity protections for pharmaceuticals (Box1).  150 
These articles and Annexe 26A would have added additional periods of protection for patent and 151 
data exclusivity for pharmaceuticals which would have delayed the introduction of generic products 152 
to the market and significantly increased the cost to health systems and consumers (Pusceddu, 153 
2018). 154 
 155 
Box 1. Relevant suspended provisions 156 




Article 18.37 Requirement for patents to be made available for either new uses of known 
products, new methods of using a known product or new processes of using a 
known product and for inventions derived from plants. 
18.46 Requirement for governments to adjust, upon request, a patent's term of 
protection to compensate the patent owner if there are unreasonable delays in 
a patent office's issuance of patents. 
18.48 Requirement to adjust a pharmaceutical patent's term of protection to 
compensate the patent owner for unreasonable curtailment of the effective 
term of a patent as a result of the marketing approval process for a 
pharmaceutical product. 
18.50 Requirement for five years protection for data and test data submitted to a 
regulatory authority for the purpose of obtaining regulatory approval to 
market a pharmaceutical product. 
18.51 Requirement for five years of protection for test or other data submitted to a 
regulatory authority for the purposes of obtaining regulatory approval to 
market a biologic pharmaceutical product. 
Annexe 26A  ‘Transparency and Procedural Fairness for Pharmaceutical Products and 
Medical Devices’ relating to the listing and pricing of pharmaceutical products 
and medical devices which would have increased and enforced the influence of 
pharmaceutical companies in the decisions of national health care authorities. 
 157 
 158 
Public health advocates and health professionals have warned that these provisions may be 159 
reinstated in the current agreement or introduced into other trade agreements (Labonté et al. 2019; 160 
Labonté, Schram & Ruckert, 2017; Tham & Ewing, 2016). Indeed, the recently signed Canada, Mexico 161 
and United States Trade Agreement (2018) includes expansions of intellectual property rights and 162 




new regulatory reforms, which introduce regulatory constraints that intrude into domestic public 163 
policy (Labonté et al. 2019).  164 
 165 
Supporters of these trade agreements claim that they will expand and grow current markets, and 166 
create new markets, while supporting the establishment of best practice regulation across signatory 167 
countries. Proponents also claim that they have the capacity to improve labour standards and 168 
working conditions across the region through the incorporation of the International Labour 169 
Organization (1998) ‘Declaration on Fundamental Principles and Rights at Work’ (Government of the 170 
Commonwealth of Australia, Department of Foreign Affairs and Trade, 2018b; Foreign Affairs 171 
Defence and Trade References Committee, 2018; Joint Standing Committee on Treaties, 2018).  172 
 173 
Researchers and scholars of public health, health systems, health policy and international law are 174 
concerned about the rapid growth in the number of trade agreements and the growing dominance 175 
of influence from markets in negotiations. These experts warn that provisions in these agreements 176 
have the potential to adversely affect access to medicines (including biologics) and medical devices, 177 
and that they will erode the capacity of governments to use regulation to address issues of public 178 
health such as highly refined foods or high sugar content beverages and foods (Crosbie, Sosa & 179 
Glantz, 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, Freeman & Bialous, 2018;  Gleeson & 180 
Friel, 2013; Gleeson, Lexchin,  Lopert, & Kilic, 2018; Gleeson,  Moir, & Lopert, 2015; Jarman, 2017; 181 
Gleeson, Lexchin, Labonté, Townsend, Gagnon, Kohler, Forman & Shadlen, 2019; Labonté et al. 182 
2019; Labonté, Schram, & Ruckert, 2016; Schram & Labonté, 2017; Schram et al. 2019;  Thow, 183 
Snowdon, Labonté, Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & Labonté, 184 
2017; Tienhaara, 2011). Other concerns have been raised by political scientists and researchers in 185 
global economic governance who consider that the broad scope of these agreements make them 186 
influential in shaping policy decisions that influence other determinants of health such as equity of 187 




access to health services, employment, pollution and the environment (Jarman, 2017; McNeill et al., 188 
2017).  189 
 190 
The majority of research to date in this rapidly evolving area of international trade has been through 191 
prospective analyses undertaken by public health and international law scholars. There is a gap in 192 
research of the potential implications particularly for the health workforce and public policy. Given 193 
the essential nature of health services and the health workforce, urgent further research of these 194 
issues is warranted. As health advocates, nurses have an important role in ensuring the 195 
sustainability, accessibility and equity of health services.  Health system sustainability is also 196 
dependent on the health professionals that deliver health care to the community. The implications 197 
for the nursing workforce, the largest group of healthcare providers, must also be considered in 198 
order to anticipate and mitigate unintended consequences that may adversely affect health systems 199 
and the health outcomes of populations. 200 
 201 
2. Method 202 
 203 
2.1 Aim 204 
The aim of this review is to explore current literature and identify existing knowledge concerning the 205 
implications of trade agreements relevant for the nursing workforce, nursing practice and public 206 
health. The 2018 Comprehensive and Progressive Agreement for Trans-Pacific Partnership (2018) 207 
will be used as an exemplar.  A scoping review protocol was developed based on The Joanna Briggs 208 
Institute Reviewers’ Manual 2015: Methodology for JBI Scoping Reviews (Peters, Godfrey, 209 
McInerney, Soares, Khalil, & Parker, 2015). 210 
  211 




2.2 Search Criteria 212 
The inclusion criteria for this review were English language, full-text, peer-reviewed journal articles, 213 
as well as grey literature including national and international policy documents published between 214 
2016 and 2019. 215 
 216 
2.3 Search strategy and outcomes 217 
Six databases were searched – Emerald Insight, Informit, Ovid-MEDLINE, ProQuest, PubMed, Scopus. 218 
Search terms included ‘trade in services agreements’, ‘free trade agreements’, ‘Trans-Pacific 219 
Partnership’ ‘TPP-11’ ‘Trans-Pacific agreement’, ‘harmonisation of regulation’, ‘regulatory 220 
coherence’, Health*, Medic*, Nurs*, ‘nurse migration’, workers, ‘workforce planning’ and variations 221 
of spelling in relation to these terms.  222 
 223 
As shown in Figure 1, 872 abstracts were sourced from the databases, and 49 additional items were 224 
sourced from grey literature using Google Scholar, hand searching and snowballing from reference 225 
lists and peer referral. After the removal of duplicates, screening of titles and review of abstracts, 139 226 
titles remained. Following full text review, a further 14 were discarded as being not relevant to context, 227 
three were discarded as not related to concept and 10 were discarded as not related to population. A 228 
total of 112 journal articles and items of grey literature were subsequently included in the review 229 
(Table 1 – Supplementary data). Each document was reviewed thoroughly, using the six-step thematic 230 
approach described by Braun & Clark (2006), in order to identify key themes relating to risks for the 231 
nursing workforce, nursing practice and public health (Table 2).  232 
  233 
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Table 2. Braun and Clarke’s (2006) six-phase framework for ‘reflexive thematic analysis’  261 
Phase Action 
1. Become familiar with the data 
2. Generate Initial Codes 
3. Search for themes 
4. Review themes 
5. Define themes 
6. Write up 
 262 
 263 
3      Results 264 
 265 
Six key themes were identified relating to risks for the nursing workforce, nursing practice and public 266 
health.  267 
 268 
3.1. Lack of consultation with health professionals and public health advocates in trade negotiations  269 
Trade agreements reflect the interests of those directly involved in the system (Schram et al, 2019). 270 
Trade negotiations are usually the responsibility of trade and finance or foreign affairs ministries of 271 
governments. Government trade negotiators are drawn from the experts in the areas of trade, finance, 272 
foreign affairs and international law rather than public health and health services (Jarman,2017). 273 
Access to trade negotiators is usually dominated by trade and finance interests. For example, the 274 
United States appointed approximately 600 corporate lobbyists as official advisors during the 275 
negotiations for the Trans-Pacific Partnership (Alcorn, 2016; Schram et al. 2019).  276 
 277 
Health advocates argue that the essential nature of health services, and the critical importance to the 278 
community, differentiates them from traditional areas involved in trade negotiations. Any intended 279 




policy change that may affect the provision of health services must, therefore, be analysed by experts 280 
in health service delivery to avoid unintended negative consequences for health systems (Alcorn, 2016; 281 
Jarman,2017; Joint Standing Committee on Treaties, 2018; Schram et al. 2019; Smith et al. 2009).  282 
 283 
Currently, opportunities for health advocates to advise on trade agreements are limited and usually 284 
occur without access to the draft agreement until late in the negotiation stage or after the agreement 285 
has been drafted (Joint Standing Committee on Treaties, 2018). Because these agreements have 286 
significant potential to affect health system resources and policies, as well as the social determinants 287 
of health, there is an urgent need for consultation with health stakeholders including public health 288 
advocates and the health professions (Jarman,2017). Some commentators consider that trade 289 
negotiations provide an important opportunity to advance the health agenda. They urge public health 290 
advocates and the health professions to engage with the process and work toward greater inclusion 291 
in these negotiations (Alcorn, 2016; Schram et al. 2019).  292 
 293 
As trade agreements evolve the potential for intrusion into domestic public policy increases the risks 294 
for public health and health services. There is a compelling need for health professions and public 295 
health advocates to have greater access to trade negotiators.  Similarly, governments need to 296 
consult with and take advice from health professions and public health experts when negotiating 297 
trade agreements in order to anticipate and avoid negative unintended consequences for 298 
communities. 299 
 300 
3.2 Implications of strengthened intellectual property provisions for equitable access to medicines 301 
(including biologics) and medical devices.  302 
Pharmaceutical companies invent new medicines (including biologics) and medical devices that may 303 
take many years and significant investment to develop, trial and produce for the market. The 304 
Agreement on Trade-Related Aspects of Intellectual Property Rights (World Trade Organization, 305 




1995) provides protections, through patents, which grant periods of 20 years monopoly rights to the 306 
inventing company. A registered patent provides the owner of the invention with the exclusive right 307 
to exploit it commercially for the life of the patent. During this time, no other company can produce 308 
a generic product for the market. This enables the company to recoup development costs and profit 309 
from the invention, thereby encouraging further investment and research.  310 
 311 
However, at the same time as the WTO introduced the Agreement on Trade-Related Aspects of 312 
Intellectual Property Rights, the world was dealing with the unprecedented health crisis of the 313 
Acquired Immune Deficiency Syndrome (AIDS), caused by the Human Immunodeficiency Virus (HIV) 314 
(t’ Hoen, 2016). Death rates from this disease were devastating for developing countries where 315 
millions of citizens were infected. The Agreement on Trade Related Intellectual Property created 316 
barriers to affordable, rapid and equitable access to cost-effective HIV medicines in many developing 317 
countries. As a result, a global campaign was launched by public health advocates, non-government 318 
organisations and health professionals, which succeeded in enabling the production of quality, 319 
generic HIV pharmaceuticals and access for millions of people to these lifesaving medicines (t’ Hoen, 320 
2016).  321 
 322 
The WTO eventually agreed on the inclusion of protections for public health in trade negotiations 323 
and a framework of rules were established. The Doha Declaration on TRIPS (Trade-Related Aspects 324 
of Intellectual Property Rights) and Public Health in 2001, and the WTO 2005 Ministerial Declaration 325 
introduced Article. 31bis to the original agreement, creating ‘compulsory licence’ granting 326 
exemption for developing countries to produce and export generic pharmaceuticals for their own 327 
population, and other developing countries in a declared health crisis (Abbott, 2006; Pusceddu, 328 
2018, ť Hoen, 2016). 329 
 330 




Data exclusivity is a second type of protection for pharmaceutical companies, which relates to the 331 
process of developing new medicines (including biologics) or medical devices through clinical trials 332 
undertaken to establish that product is safe and effective. Data exclusivity refers to the period 333 
during which another pharmaceutical manufacturer cannot rely on the data generated by the 334 
inventing pharmaceutical company to gain marketing approval for their own generic products. This 335 
means that the generic manufacturer must wait until the period of data exclusivity expires or 336 
undertake their own clinical trials before they can begin manufacturing the product. When 337 
intellectual property protections expire, these products can be produced and sold as generic brands 338 
by other companies, usually at a much-reduced cost to the consumer.  339 
 340 
Over the past two decades, pharmaceutical companies have pursued additional protections for 341 
products beyond those of the Trade-Related Aspects of Intellectual Property Rights, through the 342 
bilateral and regional trade agreements negotiated outside the WTO. The Comprehensive and 343 
Progressive Agreement for Trans-Pacific Partnership, and succeeding bilateral and regional 344 
agreements including the Comprehensive Economic and Trade Agreement (CETA) between the EU 345 
and Canada, and the United States-Mexico-Canada Agreement (USMCA), have included extended 346 
intellectual property protections. As indicated above, many of the provisions that would have 347 
enabled greater periods of exclusive patent to pharmaceutical companies were suspended in the 348 
Comprehensive and Progressive Agreement for Trans-Pacific Partnership. However, those provisions 349 
are extended and enforceable in the other trade agreements.  These “TRIPSPlus” protections include 350 
such things as increases in the length of patent periods and periods of data exclusivity (Gleeson et al, 351 
2019). 352 
 353 
There are also other areas of these agreements that enhance these protections.  These include 354 
provisions such as: 355 
 Protections for investments through investor state dispute settlement provisions 356 




 Procedural requirements for pharmaceutical pricing and reimbursement programs 357 
 Provisions with implications for regulation of pharmaceutical marketing  358 
 Regulatory requirements for assessment of safety, efficacy, and quality 359 
 Reduction/elimination of tariffs on medicines or their ingredients 360 
 Rules applying to government procurement of pharmaceuticals 361 
 Rules applying to state-owned enterprises and designated monopolies  362 
 Procedural requirements for customs administration and trade facilitation  363 
 Rules applying to regulatory practices, cooperation and coherence (Gleeson et al, 2019).  364 
 365 
Public health advocates and health professionals have expressed serious concerns about the 366 
implications of strengthened intellectual property protections in trade agreements for equity of 367 
access and cost of medicines (including biologics) and medical devices. The issue is extremely 368 
important for low and middle-income economies that rely on low cost generic medicines for the 369 
treatment of conditions such as Malaria, Tuberculosis and HIV. Any changes that further strengthen 370 
patent protections for medicines (including biologics) and medical devices put at risk the WTO Doha 371 
Declaration by creating barriers to affordable and equitable access to pharmaceuticals for 372 
communities globally (Crosbie, Sosa & Glantz 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, 373 
Freeman & Bialous, 2018;  Gleeson & Friel, 2013; Gleeson, Lexchin,  Lopert, & Kilic, 2018; Gleeson,  374 
Moir, & Lopert, 2015; Gleeson et al, 2019; Jarman, 2017; Labonté et al. 2019; Labonté, Schram, & 375 
Ruckert, 2016; Pusceddu, 2018; Schram & Labonté, 2017; McNeill et al, 2017; Schram et  al. 2019;  376 
Thow, Snowdon, Labonté, Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & 377 
Labonté, 2017; Tienhaara, 2011). 378 
 379 
From this literature review, it is clear that a conflict exists between the commercial perspective of 380 
pharmaceutical companies, the objectives of public health and public health services, and the basic 381 
human right to equitable access to medicines globally. Opinion also varies on what constitutes 382 




appropriate remuneration for the investment and research involved in inventing new 383 
pharmaceuticals and the degree to which profits translate into further investment and research 384 
(Light & Lexchin, 2012). There can be no doubt that health professionals and public health advocates 385 
must remain vigilant in all trade negotiations to prevent the introduction of provisions that can 386 
effectively limit access to and raise the cost of medicines beyond the reach of the disadvantaged in 387 
our communities.  388 
 389 
3.3 Threats to government capacity to regulate domestic public health policy from ‘Investor State 390 
Dispute Settlement’ provisions.  391 
 392 
Governments control access to their country’s markets and investments through various tariffs or 393 
quantitative restrictions on goods, and through domestic regulation. In the case of regulation, 394 
governments must balance the maintenance of domestic regulatory autonomy and liberalising 395 
access to markets and investment (Voon, 2017). Fifty years ago, an international system of arbitral 396 
jurisprudence was created to protect the rights of foreign investors from government policies and 397 
regulations that discriminate de facto against foreign goods, services or investors, or fail to meet 398 
other standards required by international economic law, such as the ‘fair and equitable treatment’ 399 
of foreign investors (Lencucha, 2017; Sheargold & Mitchell, 2016).  400 
 401 
Many countries have given investors rights to arbitration through this system of international 402 
tribunals. Called ‘Investor State Dispute Settlement’, the system has developed rapidly in the 21st 403 
century through a vast network of bilateral and multilateral trade agreements. The tribunals are 404 
arbitrated by three lawyers, usually drawn from international business law. This has led to criticism 405 
that the tribunals favour business interests and are not qualified to adjudicate on matters related to 406 
challenges to public laws and sovereignty of countries in determining domestic policy for areas such 407 
as public health and health services (Jarman, 2019; Labonté et al., 2019; Schram et al. 2019; Puig & 408 




Strezhnev, 2017). The system of arbitral jurisprudence has also been described as inconsistent, 409 
particularly in relation to the sums of compensation being awarded. Compensation payments have 410 
increased steadily from the beginning of the century to huge sums amounting to many billions of 411 
dollars. In some cases, the compensation has been far in excess of the investment. For example, 412 
Unión Fenosa Gas filed a claim against Egypt, which resulted in compensation awarded at USD 2.013 413 
billion plus interest. This sum equated to 12 percent of the country’s combined health and education 414 
budget at that time (Bonnitcha & Brewin, 2019). Arbitration tribunals also operate outside the 415 
national laws of the countries involved and have been described as undemocratic (Scram et al. 2019; 416 
Puig & Strezhnev, 2017).   417 
 418 
Health advocates have criticised Investor State Dispute Settlement provisions of trade agreements 419 
as providing a mechanism by which companies can impede government efforts to regulate in the 420 
national interest, particularly for health-related issues such as tobacco, high sugar content foods and 421 
beverages, and alcohol labelling. There is growing concern that Investor State Dispute Settlement is 422 
now increasingly encroaching on government autonomy and capacity to regulate both directly, 423 
through a growing number of challenges in international courts, and through a phenomenon called 424 
‘Regulatory Chill’ (Tienhaara, 2011; Lencucha, 2017; Crosbie & Thomson, 2018; Labonté et al. 2019; 425 
Schram & Labonté, 2017; Schram et al. 2019. ). 426 
 427 
‘Regulatory Chill’ refers to the unwillingness of government to introduce regulation for fear of a 428 
possible challenge under Investor State Dispute Settlement provisions. It has been argued that large 429 
companies have the financial capacity to use the system as a deterrent to governments and to 430 
dissuade regulation, even if they do not expect to ‘win the case’ (Lencucha, 2017). This creates a 431 
hostile regulatory environment in which governments hesitate to enact regulations in the public 432 
interest (Crosbie, Sosa & Glantz 2018; Crosbie & Thomson, 2018; Crosbie, Thomson, Freeman & 433 
Bialous, 2018; Friel, Gleeson, Thow, Labonté, Stuckler, Kay & Snowdon, 2013,  Gleeson & Friel, 2013; 434 




Gleeson, Lexchin,  Lopert, & Kilic, 2018; Gleeson,  Moir, & Lopert, 2015; Labonté, Schram, & Ruckert, 435 
2016; Labonté et al. 2019;  Schram & Labonté, 2017; Schram et al. 2019; Thow, Snowdon, Labonté, 436 
Gleeson, Stuckler, Hattersley & Friel, 2015; Thow, Jones, Hawkes, Ali & Labonté, 2017; Tienhaara, 437 
2011). 438 
 439 
Investor State Dispute Settlement provisions of trade agreements provide investors with protections 440 
against exclusionary government practices or policies. They also have the potential to influence the 441 
ways in which governments regulate domestically for the public good. The most obvious areas of 442 
concern for public health advocates, including nurses, are such things as the capacity to regulate 443 
sugar content in food and beverages or tobacco and alcohol, the environment, and pollution. There 444 
are also many other potential areas of concern such as ownership of private acute, aged care and 445 
retirement health facilities, and education and training providers responsible for educating future 446 
health professionals. 447 
 448 
3.4 Threats to government capacity to regulate domestic public health policy from ‘Regulatory 449 
Coherence’ provisions of trade agreements. 450 
 451 
Regulatory coherence is a concept that was included for the first time in the Comprehensive and 452 
Progressive Agreement for Trans-Pacific Partnership, as a way of introducing ‘best practice’ 453 
regulations across signatory countries and reducing protectionist domestic regulation. In this 454 
agreement the provisions are not legally binding. Since then, however, the provisions of ‘Regulatory 455 
Coherence’ in the recently signed United States, Mexico, Canada Agreement (2018) are expanded 456 
and are also legally binding (Labonté et al. 2019; Trans-Pacific Partnership Agreement, 2018). 457 
 458 
Regulatory coherence is another pathway through which markets can influence public policy and 459 
dissuade government regulation that impedes trade. When combined with the actual and deterrent 460 




impact of Investor State Dispute Settlement provisions, there is a significant risk for the public sector 461 
and public policy from market forces and powerful countries in such areas as public health, health 462 
services, the environment and pollution (Labonté et al. 2019).  463 
 464 
Regulation intersects with many aspects of the educational, professional and practice environment 465 
of nurses. The scope of these provisions has implications in areas including the regulation of 466 
investment in health and aged care services and the educational organisations that prepare health 467 
professionals for practice. Regulatory coherence is intended to reduce obstructive regulatory 468 
requirements that act as a barrier to trade. Regulation of the health care sector, including health 469 
service delivery, education of health professionals, and the regulation of nursing and other health 470 
professions is complex and has a primary purpose of protecting the public. The balance of 471 
opportunities and risks in the introduction of provisions that have the potential to affect health 472 
service regulation, is a key policy issue. Research into the benefits and potential unintended 473 
consequences of the introduction of regulatory coherence must be given high priority. 474 
 475 
3.5 Potential limited benefits to communities and increased health inequities.  476 
 477 
The labour provisions of the Comprehensive and Progressive Agreement for Trans Pacific 478 
Partnership have been described as “the most significant labour clause in a trade agreement 479 
concluded to date” (Tham & Ewing, 2016, p.2). The provisions address labour rights included in the 480 
‘Declaration on Fundamental Principles and Rights at Work’ (International Labour Organization, 481 
1998). They require signatory countries to have laws at the Federal level of government that 482 
enshrine the rights stated in the Declaration. Included are such important human rights as: 483 
(a) freedom of association and the effective recognition of the right to collective bargaining; 484 
(b) the elimination of all forms of forced or compulsory labour; (c) the effective abolition of 485 
child labour and, for the purposes of this Agreement, a prohibition on the worst forms of 486 




child labour; and (d) the elimination of discrimination in respect of employment and 487 
occupation (International Labour Organization, 1998).  488 
 489 
However, the obligations set out in Article 19.3 (Labour Rights) of the Comprehensive and 490 
Progressive Agreement for Trans-Pacific Partnership have been criticised for only including the 491 
International Labour Organization Declaration and not the more enforceable ‘Fundamental 492 
Conventions’ (International Labour Organization, 2002). These obligations are only enforceable 493 
where they affect trade or investment between signatory countries. Some commentators have 494 
questioned the level of adoption achievable of the labour clauses (Tham & Ewing, 2016). Others 495 
question whether access to these labour rights would be available to workers in insecure and 496 
unprotected employment, such as casual employment or working outside trade sectors directly 497 
included in the agreement. Workers in these positions could experience reduced benefits in actual 498 
health outcomes, and a decline in access to health services and health equity, relative to any 499 
material gain for the country’s economy that they may experience (McNamara and Labonté,2017; 500 
Blouin, Chopra, & van der Hoeven, R, 2009). Although the conditions under which people live, work 501 
and die are a less direct and harder to assess social determinant of health than the impact of 502 
intellectual property protections and its consequences for equity of access to medicines, they are 503 
equally important (McNeill et al. 2017). 504 
 505 
In summary, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership includes 506 
the International Labour Organization (1998) ‘Declaration on Fundamental Principles and Rights at 507 
Work’ as part of its labour provisions. These provisions are not enforceable and sections of 508 
communities may see no benefit from the inclusions or may see a deterioration in their social 509 
determinants of health. Groups such as those in insecure or unprotected work, and those working 510 
outside industries directly included in the trade agreement fall within this category. The entitlement 511 
of all workers to fundamental rights, as outlined in the ‘International Labour Organization 512 




Declaration’ (1998) and ‘Fundamental Conventions’ (2002), contribute to the social determinants of 513 
health and are of critical importance to ensuring health equity for communities.  514 
 515 
3.6 Potential implications of increased temporary migration  516 
 517 
Trade agreements include provisions for the temporary access of workers between countries.  These 518 
provisions and the specific undertakings of each country form the requirements for workers, 519 
including nurses, to move between countries that are signatory to the agreement under temporary 520 
migrant status. Often governments include a requirement for employers to demonstrate their 521 
inability to fill the positions with domestic workers, called labour market testing or economic needs 522 
testing, before contracting workers outside the domestic workforce. In the Comprehensive and 523 
Progressive Agreement for Trans-Pacific Partnership, this requirement has been waived reciprocally 524 
for six of the signatory countries - Australia, Brunei Darussalam, Canada, Japan, Malaysia, Mexico 525 
and Vietnam.  526 
 527 
In Australia, the waiver of the labour market testing requirement has caused significant concern. 528 
Many submissions to the parliamentary inquiries into the Comprehensive and Progressive 529 
Agreement for Trans-Pacific Partnership were about this issue. The Australian Nursing and Midwifery 530 
Federation expressed strong concerns for both the status and conditions of employment of 531 
temporary migrant nurses and other health workers, and the implications for the domestic nursing 532 
workforce. They asserted that, “acceptance of the need for temporary skilled migration is based on 533 
the view that appropriate policy and regulatory settings should discourage employers accessing 534 
offshore labour without first investing in training and undertaking genuine testing of the local labour 535 
market and must provide safeguards and protections for both local and overseas workers” 536 
(Australian Nursing and Midwifery Federation, 2018, p 6).  537 
 538 




Australia, Canada and Japan, like other high income developed countries are facing increased 539 
demand for health services from a rapidly ageing population (Health Workforce Australia, 2014). In 540 
the recent past, Japan has managed increased demand for nurses through economic partnerships 541 
established with Indonesia (2008), the Philippines (2008) and Vietnam (2012) for nurses to work in 542 
the caregiving facilities in the aged care sector (Ford & Kawashima, 2016). These partnerships 543 
support the immigration of nurses for temporary contracts while making no change to permanent 544 
migration (Ford, & Kawashima, 2016). This has allowed the Japanese government to avoid labour 545 
challenges from a unionised workforce and negative community attitudes to immigration. A 546 
precedent has also been set for the use of trade agreements as a mechanism for management and 547 
regulation of labour flows leading to the normalisation of migrant labour as a tradable commodity 548 
(Ford, & Kawashima,2016; Hoekman, & OeZden, 2010; Jarman, & Greer, 2010; Jurje, & Lavenex, 549 
2018; Labonté et al. 2019). 550 
 551 
The capacity to employ temporary migrant nurses offers healthcare providers increased flexibility 552 
and nursing capacity in anticipation of significant predicted shortages of nurses (Health Workforce 553 
Australia, 2014), and in recruiting to high demand specialities such as aged care and to 554 
geographically remote and rural health settings. Some commentators consider the use of trade in 555 
services agreements to facilitate worker migration as having potential for significant gains for both 556 
partner countries and individuals (Barker, 2010). However, in countries that have not included a 557 
labour market testing requirement, this will potentially bring temporary visa nurses into competition 558 
with domestic nurses for employment opportunities. The implications of a potential increase in 559 
competition for nursing employment have yet to be explored. The availability of nurses through 560 
temporary migration may lead to downward pressure on wages for nurses, and increases in 561 
casualization and insecure employment of the nursing workforce (Mashayekhi, Julsaint, & Tuerk, 562 
2006).  563 
 564 




The advantages of the temporary emigration of nurses, for source countries, include the benefit to 565 
the economy of remittances from expatriate workers, and the exchange of knowledge and 566 
technology on their return. For individual nurses, temporary migration provides an opportunity to 567 
earn wages at a higher level, for better working conditions and for professional development 568 
(Ramasamy, Krishnan, Bedford, & Bedford, 2008). The disadvantages, however, can include the 569 
depletion of adequate workers within the source country to meet its own population health needs, 570 
particularly in the public sector and remote locations.  571 
 572 
High levels of nurse emigration can also prove a significant financial burden on the country to 573 
educate and prepare nurses for both domestic and overseas demand. Outcomes depend greatly on 574 
whether the country has sufficient training capacity to educate enough nurses to support its own 575 
health care system and community as well as an emigrating population of nurses (Labonté et al., 576 
2015; Li, Nie & Li, 2014; Liua, Goryakin, Maeda, Bruckner, & Scheffler, 2016; Manning, Sidorenko, 577 
2007). Unfortunately, government health and trade portfolios are usually managed separately and 578 
there may not be harmony in policy decisions that can achieve both the health policy goals and the 579 
economic trade goal (Labonté et al., 2015; Li, Nie & Li, 2014; Liua, Goryakin, Maeda, Bruckner, & 580 
Scheffler, 2016; Manning, Sidorenko, 2007). In countries such as the Philippines, for example, the 581 
number of nurses being produced is adequate for the health system, but nurses qualify with the 582 
expectation of migrating to countries like Australia, Canada, Japan, the United Kingdom and the  583 
United States, and are supported by government policy to do so. Government health workforce 584 
strategies focused on export can frustrate efforts to ensure an adequate workforce of nurses for the 585 
home country (Yeates & Pillinger, 2018).  586 
 587 
For the destination country, reliance on temporary workers may be an economical and immediate 588 
solution to nurse shortages. However, failure to address the factors contributing to domestic nurse 589 
shortages, such as recruitment to the profession, available education places and retention of nurses 590 




in the profession is likely to lead to further long-term exacerbation of domestic shortages (Health 591 
Workforce Australia, 2014; Australian Nursing and Midwifery Federation, 2018).   592 
 593 
For individual nurses, migrating to work in another country’s health system can also have negative 594 
outcomes (Kurniati, Chen & Efendi, 2017). These can include difficulty in gaining recognition and 595 
employment at the practice level attained in the home country, potential deskilling and loss of 596 
employment opportunities on return home (Ford & Kawashima, 2016; Kurniati, Chen, Efendi, & 597 
Ogawa, 2017). For example, Indonesian nurses recruited to work in Japan’s aged care sector, under 598 
the Japan-Indonesia Economic Partnership (2008), struggled to reenter nursing practice in Indonesia 599 
at least at the level formerly achieved (Ford & Kawashima, 2016; Kurniati, Chen, Efendi, & Ogawa, 600 
2017). 601 
 602 
There are significant potential benefits and challenges from changes to the temporary migrant visa 603 
provisions of the trade agreements including the Comprehensive and Progressive Agreement for 604 
Trans-Pacific Partnership (Foreign Affairs Defence and Trade References Committee, 2018; Joint 605 
Standing Committee on Treaties, 2018). However, little is known of how these changes may affect 606 
the nursing workforce and the healthcare systems dependent upon nurses to function effectively. 607 
Further research is urgently needed to address this gap in knowledge. 608 
 609 
3. Discussion 610 
 611 
The aim of this review was to explore current literature and identify existing knowledge of the 612 
implications of trade agreements relevant to the nursing workforce, nursing practice and public 613 
health, with a particular focus on the Comprehensive and Progressive Agreement for Trans-Pacific 614 
Partnership (2018). Six themes were identified as having relevance for the nursing workforce, 615 




nursing practice and public health. Each of these falls within the scope of the definition of nursing, 616 
defined as encompassing: 617 
… autonomous and collaborative care of individuals of all ages, families, groups and 618 
communities, sick or well and in all settings. Nursing includes the promotion of health, 619 
prevention of illness, and the care of ill, disabled and dying people. Advocacy, promotion of a 620 
safe environment, research, participation in shaping health policy and in patient and health 621 
systems management, and education are also key nursing roles (ICN, 2002). 622 
 623 
The nursing profession can bring to trade negotiations the broad scope of expert knowledge and 624 
experience across all aspects of the health care environment, as well as an invaluable, multifaceted 625 
overview of a complex and interrelated system of service delivery, and environmental and social 626 
factors contributing to the health outcomes of the community. However, as has been discussed, 627 
opportunities for the health professions and public health advocates to contribute to trade 628 
agreements negotiations are currently limited (Schram et al.2019).   629 
 630 
As trade and investment intrude further into the areas of public policy areas such as public health, 631 
health service delivery and the environment, advice from groups with expertise in these sectors will 632 
be essential to prevent unintended negative consequences and enhance positive outcomes. Nurses, 633 
other health professionals and public health advocates must make the case to governments for 634 
more direct access to government trade negotiations. Governments need to be fully aware of the 635 
potential unintended implications of trade provisions, how to include special protections for health 636 
and public policy, and how the terminology used in agreement texts can ensure those protections 637 








4. Conclusion 642 
 643 
The analysis of the literature reviewed is of international importance. The essential nature of the 644 
contribution of nursing to the effective provision of accessible and equitable health care adds a 645 
degree of urgency for research evidence which will support policy makers in anticipating and 646 
responding to labour and regulatory provisions in trade agreements that may impact on the nursing 647 
workforce, nursing practice and public health. A united approach by health professional and public 648 
health associations is also likely required to ensure the necessary protection for health systems and 649 
the health of communities. 650 
 651 
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